Publication Year: 2004
DOI: https://doi.org/10.7326/0003-4819-140-6-200403160-00034
Abstract: Letters16 March PharmD, the Netherlands., and Jerry Labadie, MDFrom The Netherlands Cancer Institute, Henk 1066 CX Amsterdam, and LAREB, 5237 MH 'sHertogenbosch, the Netherlands.Author, Boot, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-140-6-200403160-00034 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack MD, CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Background: The cardiovascular side effects of PhD, fluoropyrimidines have been Show more
Authors:
Publication Year: 2018
DOI: https://doi.org/10.18632/oncotarget.25343
Abstract: // Emilie Huisman The Netherlands 3 Roche Pharma Research and Early Development, Roche 2 Innovation Center, Basel, Switzerland 4 Roche Pharma Research and Early , Development, Roche Innovation Center, Zurich, Switzerland 5 Utrecht Institute of Linda Pharmaceutical Sciences (UIPS), Utrecht, The Netherlands 6 Centre for Human J. Drug Research, Leiden, Show more
Authors:
Publication Year: 2019
DOI: https://doi.org/10.1158/1538-7445.am2019-ct073
Abstract: Abstract Background: pembrolizumab were required to have PD-L1-positive tumors (membranous PD-L1 expression in in ≥1% of tumor and associated inflammatory cells or positive staining patients in stroma); tumor PD-L1 expression was not required in KN158. with Radiographic imaging was performed Q8W for 6 mo (KN028) or advanced Q9W for 1 Show more
Authors:
Publication Year: 2010
DOI: https://doi.org/10.2174/157488410791498842
Abstract: Not available
Authors:
Publication Year: 2020
DOI: https://doi.org/10.1158/1538-7445.am2020-ct150
Abstract: Abstract Background: the previously treated advanced solid tumors: non-small cell lung cancer (NSCLC), surface squamous cell carcinoma of the head and neck, renal cell of carcinoma, melanoma (MEL), bladder cancer, soft tissue sarcoma (STS), triple-negative activated breast cancer, and MSI-high colorectal carcinoma. Dose escalation used a T continuous reassessment method Show more
Authors:
Publication Year: 2010
DOI: https://doi.org/10.7326/0003-4819-153-11-201012070-00023
Abstract: Letters7 December Treatment CX, Amsterdam, The Netherlands., Annemieke Cats, MD, PhDFrom The Netherlands After Cancer Institute, 1066 CX, Amsterdam, The Netherlands; Onze Lieve Vrouwe Severe Gasthuis, 1091 AC, Amsterdam, The Netherlands; and The Netherlands Cancer Toxicity Institute, 1066 CX, Amsterdam, The Netherlands., Henk Boot, MD, PhDFrom From The Netherlands Cancer Show more
Authors:
Publication Year: 2016
DOI: https://doi.org/10.1158/1538-7445.am2016-ct050
Abstract: Abstract BACKGROUND: bispecific no standard management options were enrolled with an initial accelerated antibody 1 pt per cohort design shifting to a 3 + with 3 design. The DLT evaluation period was 21 days ( enhanced = 1 cycle). MCLA-128 was administered every 3 weeks (q3w) antibody-dependent as an intravenous Show more
Authors:
Publication Year: 2019
DOI: https://doi.org/10.1186/s12885-019-5824-9
Abstract: Ovarian cancer female quantitative real-time PCR. BEZ235, a dual PI3K/mTOR inhibitor, was employed reproductive to investigate the role of PI3K/Akt/ mTOR signaling in regulating tract. EMT and CSC marker expression. Students' t test and one-way Chemoresistance ANOVA with Tukey's post-hoc test were used to compare the is data from different Show more
Authors:
Publication Year: 2011
DOI: https://doi.org/10.1200/jco.2010.34.1248
Abstract: The aims of 47 indications, the difference was that one agency approved an the indication, whereas the other agency did not. For the remaining European 28 indications, the same indication was approved by both of Medicines the agencies and differences were evaluated through an algorithm; in Agency 10 cases, discrepancies Show more
Authors:
Publication Year: 2019
DOI: https://doi.org/10.1158/1538-7445.sabcs18-ct073
Abstract: Background: The in to have PD-L1-positive tumors (membranous PD-L1 expression in ≥1% of patients tumor and associated inflammatory cells or positive staining in stroma); with tumor PD-L1 expression was not required in KN158. Radiographic imaging advanced was performed Q8W for 6 mo (KN028) or Q9W for SCLC 1 y (KN158), Show more
Authors:
Publication Year: 2011
DOI: https://doi.org/10.1634/theoncologist.2010-0260
Abstract: Abstract Learning be pharmacological response to a drug are, among others, nongenetic factors, able including age, gender, use of comedication, and liver and renal to: function. Nonetheless, these covariates do not explain all the observed Identify interpatient variability. Differences in genetic constitution among patients have been genetic identified to be Show more
Authors:
Publication Year: 2017
DOI: https://doi.org/10.1016/j.jtho.2016.11.301
Abstract: Not available
Authors:
Publication Year: 2013
DOI: https://doi.org/10.1016/j.ctrv.2012.12.008
Abstract: Not available
Authors:
Publication Year: 2017
DOI: https://doi.org/10.1007/s40262-017-0510-z
Abstract: Pazopanib is receptor, level ≥20 mg/L and both tumor shrinkage and progression-free survival platelet-derived has been established. At the currently approved daily dose of growth 800 mg, approximately 20% of patients do not reach this factor threshold and may be at risk of suboptimal treatment. As receptor, a result of Show more
Authors:
Publication Year: 2020
DOI: https://doi.org/10.1007/s40262-020-00858-2
Abstract: Not available
Authors:
Found 21 results in 0.111 seconds
Including any of the words AND
, OR
, or NOT
in any of your searches will enable
boolean search. Those words must be UPPERCASE. You can use this in all searches, including using
the search parameter, and using search filters.
This allows you to craft complex queries using those boolean operators along with parentheses and quotation marks.
Surrounding a phrase with quotation marks will search for an exact match of that phrase, after stemming and
stop-word removal (be sure to use double quotation marks — "
). Using parentheses will specify order of
operations for the boolean operators. Words that are not separated by one of the boolean operators will be
interpreted as AND
.
Behind the scenes, the boolean search is using Elasticsearch's query string query on the searchable fields (such as
title, abstract, and fulltext for works; see each individual entity page for specifics about that entity). Wildcard
and fuzzy searches using *
, ?
or ~
are not allowed; these characters will be
removed from any searches. These searches, even when using quotation marks, will go through the same cleaning as
described above, including stemming and removal of stop words.
Search for works that mention "elmo"
and "sesame street"
, but not the words
"cookie"
or "monster"
:
"elmo" AND "sesame street" NOT "cookie" NOT "monster"